BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34469062)

  • 1. Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease.
    He M; Li C; Tang W; Kang Y; Zuo Y; Wang Y
    Immun Inflamm Dis; 2021 Dec; 9(4):1529-1540. PubMed ID: 34469062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease.
    Xu Y; Wang S; Ye Z; Zhang H
    Front Immunol; 2024; 15():1401733. PubMed ID: 38840917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
    Park J; Chun J; Yoon H; Cheon JH
    Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
    Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
    Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
    Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
    Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
    Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
    J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
    Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
    Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
    Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
    Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.
    Cortes X; Borrás-Blasco J; Antequera B; Fernandez-Martinez S; Casterá E; Martin S; Molés JR
    J Clin Pharm Ther; 2017 Apr; 42(2):234-236. PubMed ID: 28004853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study.
    Thomann AK; Schulte LA; Globig AM; Hoffmann P; Klag T; Itzel T; Teufel A; Schreiner R; Scheffe N; Ebert MP; Wehkamp J; Gauss A; Hasselblatt P; Klaus J; Reindl W
    Z Gastroenterol; 2020 May; 58(5):439-444. PubMed ID: 32045954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
    Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
    BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated multiple microarray studies by robust rank aggregation to identify immune-associated biomarkers in Crohn's disease based on three machine learning methods.
    Chen ZA; Ma HH; Wang Y; Tian H; Mi JW; Yao DM; Yang CJ
    Sci Rep; 2023 Feb; 13(1):2694. PubMed ID: 36792688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
    Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting diagnostic biomarkers associated with immune infiltration in Crohn's disease based on machine learning and bioinformatics.
    Bao W; Wang L; Liu X; Li M
    Eur J Med Res; 2023 Jul; 28(1):255. PubMed ID: 37496049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Macaluso FS; Fries W; Viola A; Costantino G; Muscianisi M; Cappello M; Guida L; Giuffrida E; Magnano A; Pluchino D; Ferracane C; Magrì G; Di Mitri R; Mocciaro F; Privitera AC; Camilleri S; Garufi S; Renna S; Casà A; Scrivo B; Ventimiglia M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1381-1384. PubMed ID: 32981373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
    Doherty MK; Ding T; Koumpouras C; Telesco SE; Monast C; Das A; Brodmerkel C; Schloss PD
    mBio; 2018 Mar; 9(2):. PubMed ID: 29535202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.